ArticleRegenerative biomaterials2025
Recombinant human collagen type III microgel: an advanced injectable dermal filler for rejuvenating aging skin.
Article in Regenerative biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Translational Application of Recombinant Humanized Type III Collagen in Facial Rejuvenation: A Randomized Controlled Trial.Journal of cosmetic dermatology · 2025Trial
- Injection site dictates the immune response to a biodegradable polymer and corresponding collagen regeneration.Bioactive materials · 2026Article
- Mossy-textured hydroxyapatite-modified poly (lactic-co-glycolic acid) microspheres promote collagen regeneration via calcium/TGF-β and chemokine signaling pathways in soft tissue augmentation.Bioactive materials · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Skin aging, characterized by reduced collagen regeneration, chronic inflammation and heightened skin cancer risk, poses a significant challenge. Collagen-based materials, employed as dermal fillers to smooth wrinkles, have attained extensive utilization. Nevertheless, traditional animal-derived collagen protein primarily presents concerns pertaining to disease risks, potential immunological reactions, and batch instability. Here, we introduced a highly durable 1,4-butanediol diglycidyl ether cross-linked recombinant human collagen type III (rhCol III) microgel as dermal filler for rejuvenating aging skin. The rhCol III microgel exhibited exceptional thermostability, mechanical strength and injectability. Subsequently, we established a UV-photoaging skin animal model and chose rhCol III microgel as a bioactive material for
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.